{
  "docId": "019de072-e9f7-73aa-b63d-f50108da815f",
  "docSlug": "8dc30a1d33d144ab07b1459d0ae0e445",
  "documentTitle": "AstraZeneca | Investor Day Presentation Deck | 43 slides",
  "authorId": "astrazeneca",
  "authorName": "AstraZeneca",
  "documentKindSlug": "conference-presentation",
  "documentKindLabel": "Conference presentation",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2022-06-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 19,
  "pageCount": 43,
  "prevPage": 18,
  "nextPage": 20,
  "slideType": "appendix_data",
  "function": "analyze_data",
  "density": "balanced",
  "nDataPoints": 126,
  "notes": "The slide uses a forest plot to visualize hazard ratios with 95% confidence intervals for multiple clinical subgroups.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de072-e9f7-73aa-b63d-f50108da815f/19",
  "deckHref": "/decks/019de072-e9f7-73aa-b63d-f50108da815f",
  "deckJsonHref": "/decks/019de072-e9f7-73aa-b63d-f50108da815f.json",
  "deckAnchorHref": "/decks/019de072-e9f7-73aa-b63d-f50108da815f#slide-19",
  "components": [
    {
      "bbox": {
        "h": 0.68,
        "w": 0.95,
        "x": 0.03,
        "y": 0.23
      },
      "kind": "chart",
      "text": "Forest plot of hazard ratios for disease progression or death",
      "attrs": null,
      "subkind": "forest",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "6152adff-35dd-4fd9-b4a4-52dd5c62ae76",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.06,
        "w": 0.85,
        "x": 0.03,
        "y": 0.93
      },
      "kind": "disclaimer",
      "text": "PFS by blinded independent central review. Based on derived data, which includes protocol deviations. CDK4/6 = cyclin-dependent kinase 4/6; IHC = immunohistochemistry; ISH = in situ hybridization; ECOG = Eastern Cooperative Oncology Group; T-DXd = trastuzumab deruxtecan; TPC = treatment with physician's choice; mPFS = median progression-free survival; CI = confidence interval.",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "23488517-4b28-4f84-b38f-5e0c4e7c8038",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.08,
        "w": 0.45,
        "x": 0.03,
        "y": 0.05
      },
      "kind": "title",
      "text": "PFS subgroup analysis in HR+ cohort",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "e81ca116-1ec0-4296-9cbf-f68796994184",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [],
  "arcBeats": [],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}